Latest News

Research Update 02945-MOU MY1: Understanding the genetic basis of Addison’s disease in Portuguese Water Dogs

Over the first 6 months of this study, we have focused primarily on sample collection. We collected samples mostly through PWD-related channels working directly with our collaborators in the PWDF/PWDCA. We also attended the PWD National Specialty in September 2021 to promote the study and collect samples, and we established a collaboration with Dr. Anita Oberbauer at UC Davis to share samples that she had already collected. Continue reading “Research Update 02945-MOU MY1: Understanding the genetic basis of Addison’s disease in Portuguese Water Dogs”

Research Update CHF 02643-A Final: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity

The objective of the project was to examine the effects of CBD on canine cancer cell growth proliferation with aims towards understanding the signaling pathways involved and the apoptotic response related to CBD. A second aim was to understand the influence of CBD co-treatment with chemotherapeutics such as doxorubicin and vincristine. Continue reading “Research Update CHF 02643-A Final: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”

Research Update CHF 02692-A Final: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis

Between February 2019 and March 2020, 56 dogs were enrolled in the study. The amount of Δ9- tetrohydrocannabinol (THC) ingested was available for eight dogs (14%). The average dose ingested for those dogs was 175 mg (range 35-4,400). Types of sources reported included both commercial and homemade edible products (15), marijuana plant material (3), and commercial THC concentrate (1). Continue reading “Research Update CHF 02692-A Final: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis”

Research Update CHF 02553 Final: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens

We developed a comprehensive method for detecting infectious diseases in dogs, taking the guesswork out of determining which tests to use for diagnosis, and potentially improving disease surveillance because of the comprehensive nature of the test. The method is a targeted next-generation sequencing (NGS) assay, which takes advantage of the amount of data that can be generated with NGS but also includes a PCR step prior to sequencing. This reduces costs associated with the sequencing and provides adequate turn-around time for diagnostic use. Continue reading “Research Update CHF 02553 Final: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens”

Research Update CHF 02751-A FINAL: Luteinizing Hormone Receptor Activation Induces Migration and Adhesion in Neoplastic Canine Lymphocytes

In the United States, spaying and neutering of dogs and cats is commonly performed to prevent the birth of unwanted pets. However, surgically removing the ovaries or testes may have unexpected consequences. Dogs that have been spayed or neutered have an increased risk for developing obesity, urinary incontinence, hypothyroidism, hyperadrenocorticism, diabetes, cruciate ligament tears, hip dysplasia, and cancer. Lymphoma is three to four times more common in spayed and neutered dogs compared to dogs left intact. In addition, dogs that are neutered before one year of age are three times more likely to develop lymphoma than dogs neutered after one year of age. This funded study is investigating the hormonal and cellular relationships between spaying/neutering and the development of lymphoma so that new treatments will be available in the future to extend life expectancies of dogs with cancer. Continue reading “Research Update CHF 02751-A FINAL: Luteinizing Hormone Receptor Activation Induces Migration and Adhesion in Neoplastic Canine Lymphocytes”

Research Update CHF 02528 EY3: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases

Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vectorborne diseases (VBDs) are available through universities and private labs in the USA and abroad. Continue reading “Research Update CHF 02528 EY3: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”

Research Update CHF 02323 Final: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy

The preparations for the CBD epilepsy study were started in December 2017, including hiring a full-time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; we have completed the anticipated enrollment of 60 dogs. Additionally, we have been working with outside clinics in Colorado to help us in the enrollment process of the study. Three local specialty clinics with board-certified neurologists are conducting the study with CSU’s oversight at their hospitals and general veterinarians are helping with the recheck appointments and blood draws. Continue reading “Research Update CHF 02323 Final: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”

Research Update CHF 02723 EY1: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study

To date, we have screened 31 dogs for the SLIM study. Of these, 23 have met the inclusion criteria and were enrolled. Of these enrolled dogs, six dogs have completed at least 12 weeks of the 24-week clinical trial. We are averaging 1-2 dogs screening for the study per week. Therefore, we are currently on track to have all dogs enrolled by Fall 2021. Continue reading “Research Update CHF 02723 EY1: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study”

Research Update CHF 02651 Final: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling

We enrolled 30 dogs with mild to moderate atopic dermatitis and 30 healthy control animals in the study. The dogs with atopic dermatitis were treated with either Apoquel® (n=17) or Cytopoint® (n=10), whereas one dog was switched from Apoquel® to Cytopoint®, one dog was treated with prednisone followed by Apoquel®, and one dog was treated with a topical shampoo. Both Apoquel® and Cytopoint® reduced the clinical severity of the skin lesions during 8 weeks of treatment. Continue reading “Research Update CHF 02651 Final: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling”